Aptamers Engineered Nanocarriers for Cancer Therapy

Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 350 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “SERB-Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community. His Number of citations is = 26779; h-index = 85; i-10 index = 370 (According to google scholar on March 2025). He has more than 30 international publications published in very high impact factor journals (Progress in Polymer Sciences IF 32.063, Molecular Sciences IF 41.444, Progress in Material Sciences IF 48.580, Advanced Materials IF 29.4, Drug Resistance Update IF 22.841 and Material Todays IF 32.072). He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community.

• 1. Cell-SELEX technology for aptamer selection2. Biological characteristics of aptamers3. Mechanisms of multi-drug resistance of cancer4. Relevance of aptamers as targeting ligands for anticancer therapies5. Aptamers as smart ligands for nano-carriers cancer targeting6. Aptamer-functionalized liposomes for targeted cancer therapy7. Aptamer-functionalized micelles for targeted cancer therapy8. Aptamer-functionalized nanoparticles for targeted cancer therapy9. Aptamer-functionalized PLGA nanoparticles for targeted cancer therapy10. Aptamer-functionalized silica nanoparticles for targeted cancer therapy11. Aptamer-functionalized gold nanoparticles for targeted cancer therapy12. Aptamer-functionalized dendrimers for targeted cancer therapy13. Aptamer-functionalized carbon nanotubes for targeted cancer therapy14. Aptamer-functionalized quantum dots for targeted cancer therapy15. Cancer immunotherapy via nucleic acid aptamers16. Aptamer-based imaging and diagnostics for cancer cells17. Microdevice-based aptamer sensors18. Aptamer-based microfluidics for circulating tumor cells19. Aptamer-based theranostic approaches for treatment of cancer20. Challenges of aptamers as targeting ligands for anticancer therapies21. Clinical use and future perspective of aptamers